Compare Incyte Corporation (INCY) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wayfair Inc — how do they compare? Incyte Corporation trades at $120.56 (market cap $24.54B), while Wayfair Inc trades at $104.94 (market cap $14.14B). The key difference: Incyte Corporation is the larger of the two by market cap. Which is the better fit depends on your goals.
| INCY | W | |
|---|---|---|
Market Cap | $24.54B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $119.05 |
52-Week Low | $81.61 | $57.40 |
Enterprise Value | $20.04B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Wayfair (W) trades at $102.14, down 1.15% today but showing strong technical momentum with a recent golden cross signal. The company reported Q2 2026 earnings of $0.95 per share, beating estimates, with 7.5% revenue growth driven by U.S. market share gains. Despite negative net margins, operating cash flow improved to $665M in 2026, and analyst sentiment remains bullish with 51.8% buy ratings.
The outlook is cautiously optimistic with strong U.S. growth and margin expansion potential, but risks include persistent net losses, high debt-to-asset ratio of 95.1%, and international segment weakness. The consensus price target of $122 suggests 19% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
